DAXISPHARMA
ActiveSummary
DAXISPHARMA has been active since 1980 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.0m and a net result of €166,396. Equity remains stable across the filed financial years (±1.9% per year). Its solvency ranks better than 26% of 6,081 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 1.3% (low).
Directors
Board 2
Day-to-day management 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| François Vilette |
|
| Stéphane Mascarau |
|
| Ziad Matta |
|
Owners and capital
Owners
6 ownersChain of control
- SERVIER SASFR
- Servier Benelux
- DAXISPHARMA
Highest known parent: SERVIER SAS (France). The sources do not say who stands above it.
Owners 6
- Servier Beneluxparent100%
- BIOFARMAFRparentSourceown accounts 30-09-202599.57%
- SERVIER SASFRconsolidating parentconsolidates
- Servier Nederland BVNLSourceown accounts 30-09-20250.18%
- Servier Luxembourg SALUSourceown accounts 30-09-20250.14%
-
0.06%
According to the annual accounts to 30-09-2025 of DAXISPHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- Servier Benelux, SA (BE 0408.056.927) all shares
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.